{
    "name": "asparaginase Erwinia chrysanthemi",
    "comment": "Rx",
    "other_names": [
        "Erwinaze"
    ],
    "classes": [
        "Enzymes",
        "Oncology"
    ],
    "source": "https://reference.medscape.com/drug/erwinaze-asparaginase-erwinia-chrysanthemi-999704",
    "pregnancy": {
        "common": [
            "Based on findings from animal reproduction studies, therapy can cause fetal harm when administered to a pregnant woman; there are no available data use in pregnant women to evaluate drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; advise pregnant women of potential risk to fetus",
            "Pregnancy testing is recommended for females of reproductive potential before starting treatment"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Therapy can cause embryo-fetal harm when administered to pregnant women; advise females of reproductive potential to use effective contraception during treatment and for 3 months after final dose; since an indirect interaction between oral contraceptives and ddrug cannot be ruled out, a method of contraception other than oral contraceptives should be used in women of childbearing potential"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In animal reproduction studies, intramuscular administration of drug to pregnant rats and rabbits during organogenesis at doses approximately 0.005-0.5 times maximum recommended human dose resulted in structural abnormalities and embryo-fetal mortality "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence in human or animal milk, effects on breastfed child, or on milk production; because of potential for serious adverse reactions in breastfed child, advise patients that breastfeeding is not recommended during treatment and for 3 months after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "History of serious hypersensitivity reactions to asparaginase Erwinia chrysanthemi, including anaphylaxis",
                "History of serious pancreatitis with prior L-asparaginase therapy",
                "History of serious thrombosis with prior L-asparaginase therapy",
                "History of serious hemorrhagic events with prior L-asparaginase therapy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious hypersensitivity reactions, including anaphylaxis have occurred; administer in setting with resuscitation equipment; discontinue drug if hypersensitivity reaction occurs",
                "Glucose intolerance reported and in some cases, may be irreversible; monitor serum glucose levels at baseline and periodically during treatment",
                "Serious thrombotic events, including sagittal sinus thrombosis reported with both E. coli and Erwinia-derived L-asparaginase therapy; coagulation proteins were decreased in the majority of patients after a 2-week course (eg, fibrinogen, protein C activity, protein S activity, and anti-thrombin III); discontinue for a thrombotic or hemorrhagic event until symptoms resolve; after resolution, treatment may resume"
            ],
            "specific": [
                {
                    "type": "Pancreatitis",
                    "description": [
                        "Pancreatitis reported during clinical trials",
                        "Discontinue drug for severe or hemorrhagic pancreatitis manifested by abdominal pain >72 hr and amylase elevation 2.0 x ULN or more",
                        "Mild pancreatitis: hold drug until signs and symptoms subside, and amylase levels return to normal; after resolution, treatment may resume"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypersensitivity reactions",
            "percent": "17"
        },
        {
            "name": "including anaphylaxis",
            "percent": "3"
        },
        {
            "name": "Hypersensitivity",
            "percent": "4"
        },
        {
            "name": "grades",
            "percent": "5"
        },
        {
            "name": "Glucose intolerance",
            "percent": "5"
        },
        {
            "name": "Pancreatitis",
            "percent": "4"
        },
        {
            "name": "Fever",
            "percent": "3"
        },
        {
            "name": "Coagulation abnormalities",
            "percent": "3"
        },
        {
            "name": "Thrombosis",
            "percent": "2"
        },
        {
            "name": "Hyperglycemia",
            "percent": "2"
        },
        {
            "name": "Headache",
            "percent": "1"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "1"
        },
        {
            "name": "Abnormal transaminases",
            "percent": "1"
        },
        {
            "name": "Coagulation abnormalities including thrombosis and hemorrhage",
            "percent": "1"
        },
        {
            "name": "Nausea",
            "percent": "1"
        },
        {
            "name": "Vomiting",
            "percent": "1"
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "discomfort",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Local reactions",
            "percent": null
        }
    ]
}